北京启慧生物医药

Beijing Qihui Biopharmaceutical is a Chinese biotechnology company dedicated to the development of innovative mRNA-based therapeutics and vaccines. The company utilizes a proprietary platform focused on mRNA sequence optimization and advanced lipid nanoparticle (LNP) delivery systems to address unmet medical needs. Its research pipeline primarily targets infectious disease prevention, cancer immunotherapy, and protein replacement therapies for rare genetic disorders. Based in Beijing's biomedical industry hub, Qihui Biopharma aims to overcome the technical bottlenecks associated with nucleic acid drug stability and tissue-specific targeting. The company is currently advancing multiple candidates through the pre-clinical stage, focusing on establishing a robust foundation for future clinical trials. By integrating bioinformatics with molecular biology, Qihui Biopharma seeks to provide high-efficiency, low-toxicity biologic solutions.